Studies investigating SMO as a regulator found that it was often upregulated while PTCH1 was downregulated in multiple myeloma (MM) pluripotent cells, allowing for SMO to act constitutively and maintain pluripotency [133]. Here, SMO is linked to plasma cell myeloma.